1. Home
  2. TENX vs GOSS Comparison

TENX vs GOSS Comparison

Compare TENX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

BUY

Current Price

$1.49

Market Cap

74.1M

Sector

Health Care

ML Signal

BUY

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$8.55

Market Cap

70.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
GOSS
Founded
1967
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.1M
70.8M
IPO Year
2001
2018

Fundamental Metrics

Financial Performance
Metric
TENX
GOSS
Price
$1.49
$8.55
Analyst Decision
Buy
Buy
Analyst Count
10
8
Target Price
$12.56
★ $95.40
AVG Volume (30 Days)
★ 2.2M
279.9K
Earning Date
11-11-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $48,471,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.31
$0.11
52 Week High
$19.40
$12.52

Technical Indicators

Market Signals
Indicator
TENX
GOSS
Relative Strength Index (RSI) 28.27 47.73
Support Level $1.31 $0.18
Resistance Level $2.00 $12.49
Average True Range (ATR) 0.11 0.76
MACD 0.07 -0.60
Stochastic Oscillator 18.77 2.88

Price Performance

Historical Comparison
TENX
GOSS

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

Share on Social Networks: